FabriceAndre
@FAndreMD
Head of Research Division of @GustaveRoussy , @myesmo President Elect
ID:4061204056
28-10-2015 14:23:49
3,0K Tweets
13,6K Followers
518 Following
.ESMO - Eur. Oncology is launching a monthly virtual journal club. 3 papers discussed during 1h by the best experts. The goal is to update all colleagues about the latest advances wherever they are in the 🌍. First session on May ! Stay connected ! esmo.org/about-esmo-mee…
Very interesting #ESMOYOC #YO4YO session later today…looking forward to seeing you online !!!
ESMO - Eur. Oncology OncoAlert Maria Kfoury Véronique Debien Joseph Ciccolini Università di Genova Ospedale San Martino Genova francescalongo Evandro de Azambuja, MD, PhD Andres Cervantes
Unequity is the key word from the breast cancer The Lancet commission. A roadmap is proposed. ↘️ these unequities will have measurable impact on BC Survival globally. by charlotte Coles et al. V happy to have participated with Franzoi Maria Alice & Ines Vaz Luis, MD from Gustave Roussy
The #PrecisionOncology webinar presents ESMO’s new proposal for a classification of tissue-agnostic therapeutics. Register now for free and take part in this live interaction with international experts.
And that is a wrap for the Transatlantic conference between Dana-Farber Gustave Roussy around the topic of “liquid biopsies”—thank you to all the faculty, @medscape + Servier
See you next year in Paris !
#
It's today! Are you not in #Boston ❓No worries‼️It is a hybrid event! 👇
events.medscapelive.org/website/68476/
Medscape Dana-Farber Dana-Farber_GU Gustave Roussy Toni Choueiri, MD FabriceAndre
TILs = better outcome in pts with early stage TNBC who did NOT receive chemo (n=1966). A study by S Michiels Gustave Roussy and col.
Rationale for the ETNA trial testing chemo-free tt in pts with ↗️ TILs / eTNBC led by Barbara Pistilli jamanetwork.com/journals/jama/…
.Ines Vaz Luis, MD will receive a Special Award of ASCO for her role as a Mentor. She has developed a unique team of MDs, social scientists, data scientists, pts. This award illustrates the efforts of Gustave Roussy to train a new generation of colleagues.
Merci a tous les soutiens pour mon #SemiParis au profit de Gustave Roussy . Le parcours est genial mais la fin est hyper dure a cause des crampes 😩🥵
Out in ESMO Open our review on precision medicine in #breastcancer :
📍milestones of genomics to predict drug sensitivity
📍new dimensions of cancer biology
📍future directions of precision medicine
Fernanda Mosele FabriceAndre Stefan Michiels Gustave Roussy
doi.org/10.1016/j.esmo…
#RareDiseaseDay : 1 in 5 cancers are rare. The EU must act now and continue after the 2024 elections to overcome challenges for patients, researchers and healthcare professionals.
📌esmo.org/policy/rare-ca…
#ESMOTAT24 is the conference dedicated to drug development, with a large participation of Biotech / Pharma to the Scientific program and Forums of discussion. Hot topics this year were ctDNA for drug dvlpt, EU IVDR, biotech investments, dosage & comb optimisation, new Endpoints…
Ce dimanche, je courrai (lentement…) le semi marathon avec un dossard « Don Gustave Roussy « . Si certains d’entre vous veulent participer via un don ca serait genial 👇. semi-paris.dossards-solidaires.org/fundraisers/fa…
We know how will be the next Research Building Gustave Roussy (Q1 2027)
32 000 m2 , 60 research teams in 15 Centers, 15 core facilities, 1400 staff. Each floor will include 10 teams of biology that will surround Data Science / Epidemiology teams. We are welcoming new teams !
In The Lancet : Sunitinib is an option in pts w mets phaeochromocytomas and paragangliomas : 36% of pts free of progressive disease at 12 months. 1st randomized trial ever in this disease, by E Baudin Gustave Roussy and col ENDOCAN-COMET & ENSAT networks. thelancet.com/journals/lance…
.Gustave Roussy is recruiting a Clinical Investigator / Physician Scientist in Immuno-Oncology, Early Drug Development Center (DITEP). Speaking French is not mandatory at the time of recruitment. academicpositions.com/ad/institut-gu…
